Research programme: LFA-1 antagonists - ICOS

Drug Profile

Research programme: LFA-1 antagonists - ICOS

Latest Information Update: 22 Apr 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ICOS Corporation
  • Class Small molecules
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Psoriasis

Most Recent Events

  • 22 Apr 2009 No development reported - Preclinical for Psoriasis in USA (PO)
  • 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly
  • 06 Jun 2003 ICOS Corporation and Biogen have concluded their LFA-1 programme collaboration, with ICOS acquiring sole development and marketing rights to the programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top